Monoclonal antibody for generalised myasthenia gravis: implications for prescribing practice

Key Points

• The aim is to explore the implications of rozanolixizumab for prescribing practices in generalised myasthenia gravis.
• Discusses introduction and prescribing considerations for rozanolixizumab.
• Highlights treatment escalation and delivery methods.
• Focuses on patient outcomes related to new treatment options.
• Rozanolixizumab provides more choices for targeted treatments.
• Key considerations for prescribers include escalation and patient response.
• Potential for improved patient outcomes with use of rozanolixizumab.